№ lp_2_3_62724
File format: docx Character count: 2346 File size: 33 KB
A compilation of clinical trial data on CD19 CAR-T cell therapies in R/R DLBCL, FL, and MCL after second-line treatment.
Year: 2024
Region / city: N/A
Topic: Clinical trials, CAR-T therapy, cancer treatment
Document type: Research study
Organization / institution: N/A
Author: Neelapu et al., Schuster et al., Abramson et al., Jacobson et al., Fowler et al., Morschhauser et al., Wang et al.
Target audience: Oncology professionals, researchers, healthcare providers
Period of validity: N/A
Approval date: N/A
Date of changes: N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Table S1. GI50 and TGI values and doubling times for DLBCL cell lines
Year: 2013
Region / city: Global
Subject: Cancer research
Document type: Research table
Organization / institution: Cancer discovery
Author: Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, et al.
Target audience: Oncology researchers
Date of approval: 2013-03-10
Date of changes: N/A
Access to and affordability of CAR-T cell therapy in multiple myeloma: an EBMT position paper
Year: 2022
Region / city: Europe
Topic: Hematology, Multiple Myeloma, CAR-T Cell Therapy
Document Type: Position Paper
Organization: European Society for Blood and Marrow Transplantation (EBMT)
Author: Nico Gagelmann, Anna Sureda, Silvia Montoto, John Murray, Natacha Bolaños, Michelle Kenyon, Meral Beksac, Stefan Schönland, Patrick Hayden, Hans Scheurer, Kate Morgan, Laurent Garderet, Donal P. McLornan, Annalisa Ruggeri
Target Audience: Clinicians, Researchers, Healthcare Providers
Period of Action: Ongoing
Approval Date: Not specified
Date of Changes: Not specified
Overview of CAR-T Cell Therapy and Recent Advances in Cell and Gene Therapies
Year: 2025
Region / city: Philadelphia, PA
Theme: Cell and gene therapy, CAR-T cell therapy, cancer treatment
Document type: Symposium agenda
Author: Various speakers from Penn Medicine and affiliated institutions
Target audience: Hematologist-oncologists, medical oncologists, immunologists, researchers, healthcare professionals, patients and caregivers
Period of validity: April 30, 2025 - May 2, 2025
Approval date: Not specified
Date of changes: Not specified
ADVANCES IN CAR-T CELL THERAPY: EMERGING INNOVATIONS, CLINICAL PROGRESS, AND FUTURE PERSPECTIVES
Year: 2023
Region / City: Asia
Topic: Cancer Research, Cell Therapy, Immunotherapy
Document Type: Review Article
Institution: Asian Oncology Research Journal
Author: Sepideh KarkonShayan
Target Audience: Scientific Community, Oncologists, Immunologists
Period of Validity: Not specified
Approval Date: Not specified
Date of Changes: Not specified
Supplemental Methods: Monoclonal Antibodies, Cell Lines, Retroviral Vectors, and B7-H3 CAR-T Cell Generation
Section: Supplemental Methods
Field: Immunology and Hematologic Malignancies
Experimental focus: B7-H3 CAR-T cells in acute myeloid leukemia (AML)
Monoclonal antibodies: Anti-human CD markers and related reagents for flow cytometry
Suppliers: Becton-Dickinson (BD) Biosciences; Miltenyi Biotec; BioLegend; Jackson ImmunoResearch Labs
Cell lines: THP1; U937; HL-60; Kasumi-1; OCI-AML2; OCI-AML3
Primary samples: DFAM-6855; CBAM-44728 from Public Repository of Xenografts (PRoXe), Dana-Farber Cancer Institute
Biological material: Primary AML blasts; donor PBMCs; buffy coats from healthy volunteers
Vector system: SFG retroviral vector with MoMLV gag-pol and RD114 envelope
Transduction method: Retronectin-coated plates with retroviral supernatant
Cell expansion cytokines: IL7; IL15
Statistical methods: Mann Whitney test; one-way ANOVA with Holm-Sidak adjustment; Chi-square test
Software: Prism version 8 (GraphPad)
Sample origin: Bone marrow and peripheral blood from AML patients
Animal model: NSG mice for in vivo expansion of xenografts
Culture conditions: RPMI-1640 medium with fetal bovine serum, L-glutamine, penicillin, and streptomycin
BMO Ride for Cancer 2023: Establishing Atlantic Canada’s First CAR-T Therapy Lab at QEII Health Sciences Centre
Year: 2023
Event Date: September 23, 2023
Region / City: Halifax, Nova Scotia, Canada
Type: Fundraising Campaign
Organization: QEII Health Sciences Centre
Cause: Cancer Research and Treatment
Target Audience: Potential Donors and Supporters
Therapy Focus: CAR-T Cell Therapy for Blood Cancer
Objective: Establishment of CAR-T Therapy Lab and Funding Cancer Care Initiatives
Topics: CD19 DLBCL CAR-T